Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$127.29 USD

127.29
5,452,778

+1.10 (0.87%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $127.29 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance

by Zacks Equity Research

Strong performance across segments supports Anthem's (ANTM) first-quarter results.

    Zacks Equity Research

    Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered

    by Zacks Equity Research

    Centene (CNC) delivers strong first-quarter results on the back of significant membership growth.

      Zacks Equity Research

      The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

        Zacks Equity Research

        Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained

        by Zacks Equity Research

        Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.

          Zacks Equity Research

          MS, USB, ABT & TXT Leads Q1 Earnings

          by Zacks Equity Research

          MS, USB, ABT & TXT Leads Q1 Earnings

            Mark Vickery headshot

            Q1 Earnings Keep Markets in the Green: MS, USB, ABT & TXT

            by Mark Vickery

            We are still in the early stages so far, but overall results have been notably better than expected.

              Zacks Equity Research

              Abbott (ABT) Beats on Earnings and Revenues in Q1

              by Zacks Equity Research

              Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.

                Tracey Ryniec headshot

                5 Amazing Earnings Charts This Week

                by Tracey Ryniec

                It's not easy to beat the estimate nearly every quarter for years. But these 5 companies are doing it.

                  Zacks Equity Research

                  Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store?

                  by Zacks Equity Research

                  Strong revenue opportunity from various Oncology and Imaging Component products is likely to drive Varian Medical (VAR) in Q2.

                    Zacks Equity Research

                    Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

                    by Zacks Equity Research

                    Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.

                      Benjamin Rains headshot

                      3 Stocks to Buy Ahead of Earnings

                      by Benjamin Rains

                      Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won't lead to a much larger conflict. The strikes also coincided with the real start of first quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently.

                        Zacks Equity Research

                        Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?

                        by Zacks Equity Research

                        Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.

                          Zacks Equity Research

                          Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?

                          by Zacks Equity Research

                          Intuitive Surgical's (ISRG) developments on the da Vinci platform are a positive, while intense competition raises concern.

                            Zacks Equity Research

                            Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?

                            by Zacks Equity Research

                            Abbott (ABT) poised to gain on continued growth in Medical devices business in Q1.

                              Zacks Equity Research

                              Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?

                              by Zacks Equity Research

                              Abbott (ABT) poised to ride high on strength in EPD business in Q1.

                                Zacks Equity Research

                                Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?

                                by Zacks Equity Research

                                Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.

                                  Zacks Equity Research

                                  Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?

                                  by Zacks Equity Research

                                  Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.

                                    Zacks Equity Research

                                    Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device

                                    by Zacks Equity Research

                                    Abbott (ABT) adopts ways to strengthen Heart Failure business under the Medical Device segment.

                                      Urmimala Biswas headshot

                                      Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire

                                      by Urmimala Biswas

                                      Chances of a retaliation from China leads to widespread losses in the medical device sector.

                                        Zacks Equity Research

                                        Edwards (EW) Completes Enrollment for PARTNER 3 Sub-Study

                                        by Zacks Equity Research

                                        Edwards' (EW) near-term product pipeline looks quite encouraging.

                                          Zacks Equity Research

                                          Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK

                                          by Zacks Equity Research

                                          Baxter (BAX) steadily focuses on improving its Advanced Surgery business.

                                            Sweta Jaiswal headshot

                                            Can Boston Scientific's Pain be a Boon for Edwards & Others?

                                            by Sweta Jaiswal

                                            Boston Scientific delaying the re-introduction of Lotus Valve devices provides an edge to its competitors in the highly lucrative TAVR market.

                                              Zacks Equity Research

                                              Abbott's MitraClip Therapy Wins Reimbursement Nod From MHLW

                                              by Zacks Equity Research

                                              Abbott (ABT) is is leaving no stone unturned to drive its Structural Heart business.

                                                Urmimala Biswas headshot

                                                Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus

                                                by Urmimala Biswas

                                                According to Goldman Sachs, emerging markets are world's best investment in spite of several external hiccups. This comes as a breather for MedTech investors keen on exposure to emerging markets.

                                                  Sweta Jaiswal headshot

                                                  Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

                                                  by Sweta Jaiswal

                                                  Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.